希玛医疗年度报告 2024

Contents 2Corporate information4Financial highlights6Chairman’s statement9Management discussion and analysis36Profile of directors, senior management and company secretary45Report of the directors81Corporate governance report98Independent auditor’s report107Consolidated statement of comprehensive income109Consolidated statement of financial position111Consolidated statement of changes in equity113Consolidated statement of cash flows115Notes to the consolidated financial statements248Financial information summary Corporate Information公司資料 BOARD OF DIRECTORSExecutive Directors Dr. LAM Shun Chiu Dennis(Chairman and Chief Executive Officer)Ms. LI XiaotingDr. LEE Yau Wing Vincent Independent Non-executive Directors Dr. Rex AUYEUNG Pak-kuen(Vice Chairman)Mr. MA Andrew Chiu CheungMr. IP Shu Kwan StephenMr. YIN Ke BOARD COMMITTEES Audit Committee Mr. MA Andrew Chiu Cheung(Chairperson)Mr. IP Shu Kwan StephenMr. YIN Ke Remuneration Committee Mr. IP Shu Kwan Stephen(Chairperson)Ms. LI XiaotingMr. MA Andrew Chiu Cheung Nomination Committee Dr. Rex AUYEUNG Pak-kuen(Chairperson)Mr. MA Andrew Chiu CheungMr. YIN Ke AUTHORIZED REPRESENTATIVES Ms. LI XiaotingMr. CHAN Wa Ping COMPANY SECRETARYMr. CHAN Wa Ping AUDITOR PricewaterhouseCoopersCertified Public AccountantsRegistered Public Interest Entity Auditor22/F, Prince’s BuildingCentralHong Kong REGISTERED OFFICE Cricket Square, Hutchins DriveP.O. Box 2681 Grand CaymanKY1-1111Cayman Islands Cricket Square, Hutchins DriveP.O. Box 2681 Grand CaymanKY1-1111Cayman Islands PRINCIPAL PLACE OF BUSINESS AND HEADOFFICE IN HONG KONG Suite 1535, Central Building1–3 Pedder StreetHong Kong PRINCIPAL SHARE REGISTRAR Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman, KY1-1111Cayman Islands Conyers Trust Company (Cayman) LimitedCricket Square, Hutchins DriveP.O. Box 2681Grand Cayman, KY1-1111Cayman Islands HONG KONG BRANCH SHARE REGISTRAR Computershare Hong Kong Investor Services LimitedShops 1712–1716, 17th FloorHopewell Centre183 Queen’s Road EastWanchaiHong Kong 171712–1716 PRINCIPAL BANKERS The Bank of East Asia, LimitedBank of China (Hong Kong) LimitedBank of Communications Co., Ltd.Industrial and Commercial Bank of China LimitedThe Hongkong and Shanghai Banking Corporation Limited LEGAL ADVISOR ON HONG KONG LAWS Fangda Partners26th Floor, One Exchange Square8 Connaught PlaceCentral, Hong Kong 8126 COMPANY WEBSITEwww.cmermedical.com www.cmermedical.com STOCK CODE03309 03309 Financial Highlights財務概要 The board (the “Board”) of directors (the “Directors”) ofC-MER Medical Holdings Limited (the “Company”) reports theannual consolidated results of the Company and its subsidiaries(collectively, the “Group”) for the year ended 31 December 2024,together with the comparative figures for the year ended 31December 2023. Chairman’s Statement主席報告 On behalf of the Board, I hereby present to our shareholders ofthe Company the annual report of the Group for the year ended31 December 2024. In 2024, we faced various challenges such as complex globalmacroeconomic environment, fluctuating consumer confidence,and intense industry competition. Against this backdrop, theGroup insisted on prudent operations and meticulously refinedour business strategies to identify new avenues for growth withinthe ever-evolving market landscape. Leveraging C-MER’s brand, and professional and quality services,we focused our “Bright Eyes & Shiny Teeth” developmentstrategy, thereby enhancing our presence as one of the leadingHong Kong medical groups within the Guangdong-Hong Kong-Macau Greater Bay Area (the “GBA”). In addition, we prioritizedour core segments and strengthened our operations at locationsclose to the borders between Hong Kong and Shenzhen tocapture the trend of cross-border spending by Hong Kong citizens.Despite the complex and dynamic business environment, potentialopportunities remained. As a result of the improvement of the quality of the overallbusiness operations and better cost control, excluding the effectof the non-cash impairment losses of HK$182.7 million, andthe profit from the sales of medical consumables segment (ofwhich we ceased the business in the second half of 2023 due torelaxation of requirements for COVID-19 testing in Hong Kong)the profit attributable to the equity holders of the Company (the“adjusted profit for the year attributable to equity holdersof the Company”) amounted to HK$58.7 million (2023: HK$55.6million), representing a year-on-year increase of 5.7%. Ourcore medical service revenue increased by 0.5% to HK$1,913.2million from HK$1,904.5 million in 2023. To share the resultswith shareholders, the Board has resolved to recommend afinal dividend of HK2.0 cents per share for 2024, subject to theapproval of the Company’s shareholders at the annual generalmeeting to be held on Monday, 19 May 2025. STRIVED TO ENHANCE THE OPERATIONEFFICIENCY OF OUR OPHTHALMIC BUSINESS As Hong Kong’s largest and one of